Quality and scale-up bottlenecks still exist for interleukins used as ancillary materials in cell and gene therapy development. This whitepaper highlights how our whole insect-based EntoEngine protein expression platform addresses the challenges with traditional systems with IL-2, IL-10, and IL-12 as model proteins.
Common quality risks with traditional systems:
- Mammalian: High cost and risk of adventitious agents
- Bacterial: Risk of lipopolysaccharide (LPS) endotoxins
- Yeast: Hypermannosylation and immunogenic epitopes
Our fruit fly-based bioreactor ensures that the interleukins produced today are identical to those produced years later.
Offering product consistency and refining clonal validation documentation to build a stable foundation for long-term commercial supply of recombinant cytokines.
In the full whitepaper, you will find the EntoEngine approach to producing CGT ancillary materials has the following benefits:
Safe-by-Design Architecture
Modular Scalability
Regulatory Readiness
Lot Consistency
Long-Term Stability
Host Engineering Strategies